1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.

Slides:



Advertisements
Similar presentations
Tips to a Successful Monitoring Visit
Advertisements

Marc Bailie DVM, PhD Director In Vivo Facility Michigan State University, Chief Development Officer Integrated Nonclinical Development Solutions (INDS)
Regulatory Framework Leigh Shaw, Director.
Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
The IND and Clinical Trial Management Frances Richmond Director International Center for Clinical Trials.
Strengthening the Medical Device Clinical Trial Enterprise
1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
Regulatory Compliant Performance Improvement for Pharmaceutical Plants AIChE New Jersey Section 01/13/2004 Murugan Govindasamy Pfizer Inc.
Establish Verification Procedures (Task 11 / Principle 6)
1 Investigator-Initiated Clinical Research Planning, Developing, Conducting, Managing, and Succeeding Wm. Hirschhorn, M.S. Director, OCT & RQI and Adj.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Special Topics in IND Regulation
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Stefan Franzén Introduction to clinical trials.
Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.
MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.
Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.
Investigational New Drug Application 21 CFR Part 312 A Review for OCRA US RAC Study Group September 2005 Ginger Clasby, MS Promedica International
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Good Clinical Practice GCP
Good Laboratory Practices (GLPs)
Guidance for Industry M4S: The CTD-Safety
Regulatory Overview.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Pre-Award Issues Related to Human Research and Animal Use March 15, 2013.
Stefan Franzén Introduction to clinical trials.
Investigational New Drug Application (IND)
Exploratory IND Studies
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
FDA Recommendations: Sampling Plans for Blood Establishments Lore Fields MT(ASCP)SBB Consumer Safety Officer OBRR/CBER/FDA October 19, 2012.
MEDICAL experts INDUSTRY Some of our clients. Pharmaceutical companies, manufacturers of medical and surgical devices, clinical research organizations,
1 Denise K. Thwing, MAS, RN, CCRA March 31, 2010 Version: Final 31-Mar-2010.
QSR and GLP What exactly are these?.
THE BIOTECHNOLOGY WORKPLACE. OVERVIEW Biotechnology workplaces Laboratories.
Overview of FDA's Regulatory Framework for PET Drugs
1/33.  What is INDA ?  Types of INDAs  Objectives of INDAs  Format & Contents of an INDA  IND Safety reports  IND Annual Reports  IND Review Process.
Molecule-to-Market-Place Quality
The New Drug Development Process (www. fda. gov/cder/handbook/develop
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Agenda for Session Compliance in Clinical Research
Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.
1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Drug Development and IND Process GC 690 Walter Kraft, MD.
COPYRIGHT ALL RIGHTS RESERVED. LEGAL DISCLOSURE. November 25, 2002 PRESENTATION TO: Public Hearing: FDA Regulation of Combination Products November.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
E-Clinical
Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.
Good Laboratory Practice - general information Pirkko Puranen Senior Inspector, Ph.D. Inspectorate.
GCP (GOOD CLINICAL PRACTISE)
The Regulation on Cell Therapy Products in Japan
נמטוציטים משושנת ים Eli. S Lec. No.2.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
Pre-Investigational New Drug (pre-IND) Meeting with FDA
The Information Professional’s Role in Product Safety
FDA’s IDE Decisions and Communications
Erica Takai, PhD for Andrew Farb, M.D.
Good Laboratory Practices
Timothy B. Cleary, Esq. Meredith Manning, Esq.
Computer System Validation
Aerodrome Certification Workshop
Presentation transcript:

1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI BioPharma, Inc. Portland, OR Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI BioPharma, Inc. Portland, OR

2 Overview Definitions Elements Concepts Application Challenges Pitfalls Summing it Up But first……… Definitions Elements Concepts Application Challenges Pitfalls Summing it Up But first………

3 Who Am I? 25+ years in the industry Ethical drugs, biologics, devices Degrees from U of W Married with 2 dogs and 4 cats 25+ years in the industry Ethical drugs, biologics, devices Degrees from U of W Married with 2 dogs and 4 cats

4 GLPs: Definition Basis: 21 CFR Part 58: GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES GLPs: Good Laboratory Practices Nonclinical laboratory study means in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety. The term does not include studies utilizing human subjects or clinical studies or field trials in animals. The term does not include basic exploratory studies carried out to determine whether a test article has any potential utility or to determine physical or chemical characteristics of a test article. Basis: 21 CFR Part 58: GOOD LABORATORY PRACTICE FOR NONCLINICAL LABORATORY STUDIES GLPs: Good Laboratory Practices Nonclinical laboratory study means in vivo or in vitro experiments in which test articles are studied prospectively in test systems under laboratory conditions to determine their safety. The term does not include studies utilizing human subjects or clinical studies or field trials in animals. The term does not include basic exploratory studies carried out to determine whether a test article has any potential utility or to determine physical or chemical characteristics of a test article.

5 Experiment “An operation carried out under controlled conditions in order to discover an unknown effect or law, to test or establish a hypothesis, or to illustrate a known law.” Merriam-Webster “An operation carried out under controlled conditions in order to discover an unknown effect or law, to test or establish a hypothesis, or to illustrate a known law.” Merriam-Webster

6 “GLP” is Misused GLP does not mean:  Requirements for recording QC data  Requirements for any laboratory work (e.g., R&D or QC)  Definition of a material grade (“GLP-grade”) GLP does not pertain to ANYTHING other than a nonclinical laboratory study. GLP does not mean:  Requirements for recording QC data  Requirements for any laboratory work (e.g., R&D or QC)  Definition of a material grade (“GLP-grade”) GLP does not pertain to ANYTHING other than a nonclinical laboratory study.

7 Concepts GLPs have more specific requirements, compared with other regulations. GLPs apply only to nonclinical safety studies. GLP studies can be in vitro or in vivo. Nonclinical studies are critical to any clinical study leading through market application (drug, devices, biologics). GLPs have more specific requirements, compared with other regulations. GLPs apply only to nonclinical safety studies. GLP studies can be in vitro or in vivo. Nonclinical studies are critical to any clinical study leading through market application (drug, devices, biologics).

8 Application IND Enabling Studies  Toxicology  Safety Pharmacology  Genotoxicity Marketing Application Studies  Long-term toxicity  Carcinogenicity  Reproductive toxicity IND Enabling Studies  Toxicology  Safety Pharmacology  Genotoxicity Marketing Application Studies  Long-term toxicity  Carcinogenicity  Reproductive toxicity

9 Applications - Details Protocol format is defined  Use it - the reviewers expect information provided in a consistent manner for everyone.  Think it through - deviations can be perceived negatively.  Prepare and approve protocol BEFORE starting work (contractors expect this). Protocol format is defined  Use it - the reviewers expect information provided in a consistent manner for everyone.  Think it through - deviations can be perceived negatively.  Prepare and approve protocol BEFORE starting work (contractors expect this).

10 More Details Quality Assurance Unit  Responsibilities defined  Study audits  Master Schedule  Report to management  Final Report review/sign-off Quality Assurance Unit  Responsibilities defined  Study audits  Master Schedule  Report to management  Final Report review/sign-off

11 More Details Study Director  The buck stops there  Protocol  Study execution  Final Report Study Director  The buck stops there  Protocol  Study execution  Final Report

12 Other Details from GLPs Animal Care Standard operating Procedures Records Equipment Analytical methods (from a guidance document) Disqualification Animal Care Standard operating Procedures Records Equipment Analytical methods (from a guidance document) Disqualification

13 Challenges An IND/IDE/IAND-enabling study requires an articulation of the anticipated clinical plan.  Route of administration  Dose schedule  Formulation  Uses material representative of what will be use in the clinic An IND/IDE/IAND-enabling study requires an articulation of the anticipated clinical plan.  Route of administration  Dose schedule  Formulation  Uses material representative of what will be use in the clinic

14 Challenges (continued) For a small company, there is a tendency to want the lowest cost - but you may pay for it later. Apply the old adage: Fast CheapPICK-TWO GLP-compliant For a small company, there is a tendency to want the lowest cost - but you may pay for it later. Apply the old adage: Fast CheapPICK-TWO GLP-compliant

15 Pitfalls Not ensuring the test article is representative of the process, materials, etc., of the clinical product  You may have to repeat the study  Your clinical study could be delayed Not using the data obtained from the study to establish monitoring in the human study. Not reporting safety issues from a GLP study while the clinical study is occurring. Not ensuring the test article is representative of the process, materials, etc., of the clinical product  You may have to repeat the study  Your clinical study could be delayed Not using the data obtained from the study to establish monitoring in the human study. Not reporting safety issues from a GLP study while the clinical study is occurring.

16 More Pitfalls Assuming the contract lab knows what they’re doing (trust but verify) Not seeking FDA concurrence of the study design before starting (risky) Not carefully reviewing the draft report before sending it to FDA. Not reporting ALL data obtained from a nonclinical study - you can discount it but you must report it. Assuming the contract lab knows what they’re doing (trust but verify) Not seeking FDA concurrence of the study design before starting (risky) Not carefully reviewing the draft report before sending it to FDA. Not reporting ALL data obtained from a nonclinical study - you can discount it but you must report it.

17 Summing it Up… GLPs are specific in their requirements GLPs are critical to clinical trial subject safety GLP studies are critical elements for an IND, leading to market approval. GLPs are specific in their requirements GLPs are critical to clinical trial subject safety GLP studies are critical elements for an IND, leading to market approval.